Ethylene Oxide Residual Testing India | Medical Devices | NABL

Auriga Research provides NABL-accredited ethylene oxide (EO) residual testing for medical devices per ISO 10993-7. Our analytical laboratory quantifies EO, ethylene chlorohydrin (ECH), and ethylene glycol (EG) residues using GC-FID and headspace GC-MS — ensuring EO-sterilised devices meet safety limits before patient contact.

EO sterilisation is used for over 50% of medical devices globally, but residual EO is a known carcinogen and mutagen. Regulatory bodies including CDSCO, US FDA, and EU MDR mandate quantitative EO residual testing as part of device release and registration dossiers. Our validated extraction and analysis methods cover all device types — from simple disposables to complex implantable devices.

EO Residual Testing Parameters

Ethylene oxide (EO) — headspace GC-FID / GC-MS
Ethylene chlorohydrin (ECH) — solvent extraction with GC-FID
Ethylene glycol (EG) — solvent extraction with GC-FID
Extraction method validation for device-specific geometry
Simulated-use extraction conditions per ISO 10993-12
Accelerated and real-time aeration studies
Dissipation curve determination for aeration cycle optimisation

Who Needs EO Residual Testing

Medical device manufacturers using EO sterilisation
Contract sterilisation facilities validating aeration cycles
Companies filing CDSCO, FDA 510(k), or EU MDR technical documentation
Quality teams conducting routine batch release testing
Implant manufacturers requiring stringent EO limit compliance

Turnaround Time

Standard EO residual analysis (EO, ECH, EG) takes 7-10 business days. Extraction method validation takes 15-20 business days. Dissipation curve studies (multiple time-point analyses) take 20-30 business days depending on the number of aeration intervals tested.

Related Services

Frequently Asked Questions

What is ethylene oxide residual testing and why is it mandatory?

Ethylene oxide (EO) sterilisation leaves chemical residues — EO, ethylene chlorohydrin (ECH), and ethylene glycol (EG) — on medical devices. These residues are toxic and can cause irritation, sensitisation, or carcinogenic effects in patients. ISO 10993-7 sets maximum allowable limits based on device contact type and duration. CDSCO, FDA, and EU MDR require EO residual testing for all EO-sterilised devices before market release.

What are the ISO 10993-7 limits for EO residuals?

ISO 10993-7 specifies maximum allowable doses based on exposure category. For permanent contact devices, the EO limit is 0.1 mg per device per day (average dose). For limited contact devices (under 24 hours), the limit is 4 mg per device. ECH limits are 9.4 mg per day for limited contact and 0.4 mg per day for prolonged contact. These limits consider both the total residue per device and the patient exposure duration.

How is EO residual testing performed?

Device samples are extracted in an appropriate solvent (typically water or dimethyl sulfoxide) under defined temperature and time conditions. The extract is analysed by gas chromatography with flame ionisation detection (GC-FID) or headspace GC-MS for EO quantification. ECH and EG are determined simultaneously. The extraction method is validated for the specific device geometry and material to ensure complete recovery of residuals.